Close Menu

neurological disorders

The two California firms are linking their bioinformatics platforms in hopes of accelerating biomarker and drug discovery processes for pharma companies.

With its recent $50 million VC round, the British bioinformatics firm is targeting growth in new applications as it accelerates tertiary data analysis.

Twist will give Takeda access to its phage display libraries to help Takeda discover and validate antibodies needed for the development of new biologics. 

The partners aim to develop unbiased omics-based methods for identifying cases of PTSD, which may increase in the wake of the COVID-19 pandemic.

Exome sequences for nearly 35,600 cases and controls revealed genes prone to mutation in autism spectrum disorder, along with related cell types, functions, and developmental stages.

Researchers in the US and the United Arab Emirates found that RNA-seq in B-lymphoblastoid cell lines can help identify pathogenic variants that DNA testing missed.

Run by the Simons Foundation Autism Research Initiative, SPARK has already grown to more than 220,000 participants from 75,000 families living in the US.

The longtime quest of one Microsoft data scientist to stop infant crib deaths has grown into a genomics and AI research program with lofty goals.

During the five-year collaboration, the partners will research disease-causing gene mutations and develop new CRISPR-based technologies for drug discovery.

The study, which is recruiting 1,130 children with undiagnosed genetic diseases, is testing two web-based interactive tools.

Pages

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.